Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;30(6):1069-1076.
doi: 10.3201/eid3006.231338.

Decolonization and Pathogen Reduction Approaches to Prevent Antimicrobial Resistance and Healthcare-Associated Infections

Review

Decolonization and Pathogen Reduction Approaches to Prevent Antimicrobial Resistance and Healthcare-Associated Infections

Mihnea R Mangalea et al. Emerg Infect Dis. 2024 Jun.

Abstract

Antimicrobial resistance in healthcare-associated bacterial pathogens and the infections they cause are major public health threats affecting nearly all healthcare facilities. Antimicrobial-resistant bacterial infections can occur when colonizing pathogenic bacteria that normally make up a small fraction of the human microbiota increase in number in response to clinical perturbations. Such infections are especially likely when pathogens are resistant to the collateral effects of antimicrobial agents that disrupt the human microbiome, resulting in loss of colonization resistance, a key host defense. Pathogen reduction is an emerging strategy to prevent transmission of, and infection with, antimicrobial-resistant healthcare-associated pathogens. We describe the basis for pathogen reduction as an overall prevention strategy, the evidence for its effectiveness, and the role of the human microbiome in colonization resistance that also reduces the risk for infection once colonized. In addition, we explore ideal attributes of current and future pathogen-reducing approaches.

Keywords: Pathogen reduction; antimicrobial resistance; bacteria; decolonization; healthcare-associated infection; human microbiome; patient safety; transmission prevention.

PubMed Disclaimer

Figures

Figure
Figure
Preferred attributes for decolonization and pathogen reduction approaches to prevent antimicrobial resistance and healthcare-associated infections. Examples of these approaches include the following: highly selective, e.g., selective digestive decontamination targeting aerobic gram-negative bacilli; limited distribution, e.g., nonabsorbable antimicrobial drugs; avoids cross-resistance, e.g., chlorhexidine biocide; high potency, e.g., preventing selection of resistant mutations; stable or reproducible, e.g., use of phages to decolonize or reduce bacterial burden; and microbiome protective, e.g., using the human microbiome to spare beneficial microbes.

Similar articles

Cited by

References

    1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. [cited 2023 Jul 20]. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-re...
    1. Centers for Disease Control and Prevention. COVID-19 U.S. impact on antimicrobial resistance: 2022. special report [cited 2023 Jul 20]. https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf
    1. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. ; Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–55. 10.1016/S0140-6736(21)02724-0 - DOI - PMC - PubMed
    1. Shimasaki T, Seekatz A, Bassis C, Rhee Y, Yelin RD, Fogg L, et al. ; Centers for Disease Control and Prevention Epicenters Program. Increased relative abundance of Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae within the gut microbiota is associated with risk of bloodstream infection in long-term acute care hospital patients. Clin Infect Dis. 2019;68:2053–9. 10.1093/cid/ciy796 - DOI - PMC - PubMed
    1. Fishbein SRS, Hink T, Reske KA, Cass C, Struttmann E, Iqbal ZH, et al. Randomized controlled trial of oral vancomycin treatment in Clostridioides difficile–colonized patients. MSphere. 2021;6:e00936–20. 10.1128/mSphere.00936-20 - DOI - PMC - PubMed

MeSH terms

Substances